US Patent No. 9,428,523

2-AMINO-6-METHYL-4,4A,5,6-TETRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL-1,3-THIAZOL-4-YL AMIDES


Patent No. 9,428,523
Issue Date August 30, 2016
Title 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl Amides
Inventorship Michael Aaron Brodney, Newton, MA (US)
Elizabeth Mary Beck, Edinburgh (GB)
Christopher Ryan Butler, Canton, MA (US)
Lei Zhang, Auburndale, MA (US)
Gabriela Barreiro, Rio de Janerio (BR)
Erik Alphie LaChapelle, Uncasville, CT (US)
Bruce Nelsen Rogers, Belmont, MA (US)
Assignee Pfizer Inc., New York, NY (US)

Claim of US Patent No. 9,428,523

1. A pharmaceutical composition comprising a compound of Formula I
wherein
R1 is selected from the group consisting of:

phenyl optionally substituted with one to three R2;

C3-6cycloalkyl optionally substituted with one to three R2; and

a 5- to 10-membered heteroaryl, having one to four heteroatoms independently selected from N, O or S, wherein at least one
of the heteroatoms is N and wherein said N is optionally substituted with R3; and wherein said 5- to 10-membered heteroaryl is optionally substituted on carbon with one to three R2;

R2 at each occurrence is independently selected from the group consisting of halogen, hydroxy, cyano, C1-6alkyl, C1-6alkoxy, C3-6alkenyl, C3-6alkenyloxy, C3-6alkynyl, C3-6alkynyloxy, C1-6alkoxy-C1-6alkyl, C3-6cycloalkoxy, C3-6cycloalkyl, C3-6cycloalkyl-C1-6alkyl, C3-6cycloalkyl-C1-6alkoxy, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-6alkyl; wherein said C1-6alkyl, C1-6alkoxy, C3-6alkenyl, C3-6alkenyloxy, C3-6alkynyl, C3-6alkynyloxy, C1-6alkoxy-C1-6alkyl, C3-6cycloalkoxy, C3-6cycloalkyl, C3-6cycloalkyl-C1-6alkyl, C3-6cycloalkyl-C1-6alkoxy, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-6alkyl are each optionally substituted with one to three substituents independently selected from fluoro, chloro, hydroxy,
methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluoromethoxy; or two
R2 groups taken together can be a C3-5alkylene; and

R3 is selected from the group consisting of hydrogen, C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C1-6alkoxy-C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-6alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-6alkyl; wherein said C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C1-6alkoxy-C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-6alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-6alkyl are each optionally substituted with one to three substituents independently selected from fluoro, chloro, hydroxy,
methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluoromethoxy; or R3 and R2 taken together can be a C3-5alkylene;

or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer,
and a pharmaceutically acceptable vehicle, diluent or carrier.